Expert Forum on Bladder Cancer: The BCG shortage
“Fortunately, since things have…eased up with the pandemic, I would say probably in the last 6 months I've noticed that the BCG availability has improved,” says Chad R. Ritch, MD, MBA, FACS.
EP: 1.Expert Forum on Bladder Cancer: The BCG shortage
EP: 2.Expert Forum on Bladder Cancer: Bladder-sparing treatment
EP: 3.Expert Forum on Bladder Cancer: Nadofaragene Firadenovec for BCG-unresponsive NMIBC
EP: 4.Expert Forum on Bladder Cancer: Recent FDA approvals
EP: 5.Expert Forum on Bladder Cancer: Recent Innovations
EP: 6.Expert Forum on Bladder Cancer: Future Innovations
In part 1 of our 6-part series: Expert Forum: Bladder Cancer, Chad R. Ritch, MD, MBA, FACS, discusses how his own experience with the BCG shortage has forced him to adapt in order to meet the needs of his patients. The full series also features Sam S. Chang, MD, MBA, and Chris B. Anderson, MD, MPH.
Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. Ritch is an associate professor of urology and an associate director of UHealth International at the Miller School of Medicine, University of Miami, Florida. Anderson is an assistant professor of urology at Columbia University Irving Medical Center, Columbia University, New York City, New York.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
